BioCryst Pharmaceuticals Form 4 Filings Shows CCO Charles K Gayer Bought 30,000 Shares At An Average Price Of $5.47/Share; CEO Jon P Stonehouse Bought 30,000 Shares At An Average Price Of $5.55/Share; Steven K Galson Bought 21,940 Shares At An Average Price Of $5.49/Share; Helen M. Thackray Bought 30,000 Shares At An Average Price Of $5.86/Share; Anthony Doyle Bought 36,300 Shares At An Average Price Of $5.57/Share
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals' recent SEC Form 4 filings reveal significant insider buying activity. Key executives, including the CCO, CEO, and other senior officers, have collectively purchased over 148,000 shares at prices ranging from $5.47 to $5.86 per share.
May 15, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals' insiders, including the CEO and CCO, have purchased over 148,000 shares at prices between $5.47 and $5.86. This significant insider buying activity may indicate confidence in the company's future prospects.
Insider buying is often seen as a positive signal by investors, indicating that those with the most knowledge of the company believe in its future prospects. The significant volume of shares purchased by multiple senior executives suggests strong internal confidence, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100